Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01956812
Title Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1)
Acronym PANCRIT®-1
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Age Groups: adult
Covered Countries USA | FRA | ESP | CAN | BEL | AUT

No variant requirements are available.